ClinicalTrials.gg
RecruitingNCT05448365Updated Feb 12, 2026

Vitamin D, Epigallocatechin Gallate, D-chiro-inositol and Vitamin B6 in Uterine Fibroid

An interventional study of Epigallocatechin gallate, Vitamin D, Vitamin B6, D-chiro-inositol and Placebo in Uterine Fibroids, D-chiro-inositol and Inositol, sponsored by Lo.Li.Pharma s.r.l. Recruiting at 2 sites in Italy. Open to female participants aged 30 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-02-12.

Sponsored by Lo.Li.Pharma s.r.l · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as recruiting.
  • Started Jul 2022; still recruiting 4 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
30 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Leiomyoma with a site in Italy — 5 open to participants now, 5 under way, none of them phase 3. Leiomyoma · Italy.

Planned enrollment
15th of 18
60 · median 133
Started
2022
with 1 other
No phase
8 of 30
2 open now
Registered
24th of 30
by date

Among the 30 studies in Leiomyoma with a site in Italy, this one is the 15th largest by planned enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2022, is one of 8 with no phase, and was the 24th registered.

Leiomyoma

439 studies on the registry are indexed under Leiomyoma; 74 are open to participants now.

Browse Leiomyoma studies →

Open to participants now

5 of the 30 studies in Leiomyoma with a site in Italy are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 44 Leiomyoma studies recruiting now, 23 (52%) set no upper age limit and 20 (45%) stop at 75 or younger; 4 take children under 18; 9 take healthy volunteers.

This study: 30 Years to 40 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Leiomyoma with a site in Italy, or all of them as a file.
02

Study summary

The study will evaluate the impact on uterine fibroids' volume of a combination of natural molecules including Epigallocatechin gallate, Vitamin D, D-chiro-inositol and Vitamin B6.

The patients will be evaluated at baseline and after three months of treatment with placebo or product.

03

Conditions studied

  • Uterine Fibroids
  • D-chiro-inositol
  • Inositol
  • Epigallocatechin Gallate
  • Vitamin D
  • Vitamin B6

Browse trials for

04

Who can participate

Ages eligible
30 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. uterine fibroid with diameter greater than or equal to 4cm or multiple fibroids
  2. eligible for surgery
  3. symptoms like menometrorrhagia or pelvic pain

Exclusion criteria

Exclusion Criteria:

  1. >30
  2. currently pregnant or breastfeeding
  3. diabetic
  4. suspect of
  5. diagnosis of cancer
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    EGCG, Vit D, DCI, Vit B6

    Women with uterine fibroids randomized to treatment group

    Dietary Supplement: Epigallocatechin gallate, Vitamin D, Vitamin B6, D-chiro-inositol

  • Placebo comparator
    Placebo

    Women with uterine fibroids randomized to placebo group

    Dietary Supplement: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Diameter

    Greater diameter of the diagnosed uterine fibroids

    Time frame: 3 months

Secondary outcomes

  1. Volume

    Total volume of the diagnosed uterine fibroids

    Time frame: 3 months

  2. Need for surgery

    The percentage of patients that decide to avoid surgery

    Time frame: 3 months

  3. pVEGF-R

    the phosphorilation of VEGF receptor

    Time frame: 3 months

  4. Marker of cellular proliferation

    expression of ki67, ER, PR

    Time frame: 3 months

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2022 (actual). Primary completion is estimated for Mar 2026, 44 months after the start.

Of 58 interventional studies with no phase under Leiomyoma, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 72. This study's planned 44 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 4, 2022
First posted
Jul 7, 2022
StartActual
Jul 1, 2022
Primary completionEst.
Mar 1, 2026
CompletionEst.
Jul 1, 2026
Last update
Feb 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05448365
Lead sponsor
Lo.Li.Pharma s.r.l
Responsible party
Sponsor
First posted
Jul 7, 2022
Start date
Jul 1, 2022
Primary completion
Mar 1, 2026 (estimated)
Completion
Jul 1, 2026 (estimated)
Last update
Feb 12, 2026

Study contacts

Massimo Stomati, Ph. D
Contact
mstomati@gmail.com
0831851303
Andrea Tinelli, Ph. D
Contact
andreatinelli@gmail.com
0832394507

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Epigallocatechin gallate · Vitamin D · Vitamin B 6 · Pyridoxine · Chiro-inositol, (+)-

Start the discussion